Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After football on WRAL: Patchy fog to start the school year. Where your kids will be likely to see it at the bus stop.
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
132.89
+2.83 (+2.18%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corp
< Previous
1
2
3
4
5
6
7
8
Next >
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
December 21, 2023
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Unveiling 7 Analyst Insights On Glaukos
December 21, 2023
Via
Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 20, 2023
From
Glaukos Corporation
Via
Business Wire
iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
December 15, 2023
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog...
Via
Benzinga
Exposures
Product Safety
Analyst Ratings for Glaukos
November 28, 2023
Via
Benzinga
4 Analysts Have This to Say About Glaukos
November 08, 2023
Via
Benzinga
8 Analysts Have This to Say About Glaukos
September 26, 2023
Via
Benzinga
Dow Extends Rally As Treasury Yields Tank
December 14, 2023
The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision.
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
December 14, 2023
The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for...
Via
Benzinga
Exposures
Product Safety
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
December 14, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Stifel Healthcare Conference
November 07, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos's Earnings Outlook
August 01, 2023
Via
Benzinga
Analyst Ratings for Glaukos
July 31, 2023
Via
Benzinga
Where Glaukos Stands With Analysts
July 14, 2023
Via
Benzinga
Stifel Maintains Buy Rating for Glaukos: Here's What You Need To Know
June 26, 2023
Via
Benzinga
Glaukos Announces Third Quarter 2023 Financial Results
November 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
October 31, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
October 11, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 23, 2023
From
Glaukos Corporation
Via
Business Wire
8 Analysts Have This to Say About Glaukos
June 26, 2023
Via
Benzinga
Analyst Expectations for Glaukos's Future
June 05, 2023
Via
Benzinga
Glaukos Announces Second Quarter 2023 Financial Results
August 02, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
July 19, 2023
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...
Via
Benzinga
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
July 17, 2023
From
Glaukos Corporation
Via
Business Wire
These 2 Soaring Stocks Finished the Week Strong
July 14, 2023
Wall Street coasted into the close on Friday but still had a good week.
Via
The Motley Fool
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
July 14, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
July 12, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock Upgrade
June 07, 2023
Piper Sandler has upgraded Glaukos Corporation (NYSE: GKOS) to Overweight from a Neutral ra
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
June 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.